MA45672A - Anticorps multispécifiques dirigés contre cd40 et cd137 - Google Patents

Anticorps multispécifiques dirigés contre cd40 et cd137

Info

Publication number
MA45672A
MA45672A MA045672A MA45672A MA45672A MA 45672 A MA45672 A MA 45672A MA 045672 A MA045672 A MA 045672A MA 45672 A MA45672 A MA 45672A MA 45672 A MA45672 A MA 45672A
Authority
MA
Morocco
Prior art keywords
directed against
antibodies directed
multispecific antibodies
multispecific
directed
Prior art date
Application number
MA045672A
Other languages
English (en)
Inventor
Isil Altintas
Friederike Gieseke
Paul Parren
Rik Rademaker
Ugur Sahin
David Satijn
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of MA45672A publication Critical patent/MA45672A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
MA045672A 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137 MA45672A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016066840 2016-07-14

Publications (1)

Publication Number Publication Date
MA45672A true MA45672A (fr) 2019-05-22

Family

ID=59501399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045672A MA45672A (fr) 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137

Country Status (22)

Country Link
US (6) US11091557B2 (fr)
EP (2) EP4755464A3 (fr)
JP (3) JP7138630B2 (fr)
KR (3) KR20240017129A (fr)
CN (2) CN117247458A (fr)
AU (2) AU2017296095C1 (fr)
BR (1) BR112019000512A2 (fr)
CA (1) CA3030636A1 (fr)
DK (1) DK3484922T3 (fr)
EA (1) EA201990293A1 (fr)
ES (1) ES3072652T3 (fr)
FI (1) FI3484922T3 (fr)
IL (1) IL264142B2 (fr)
LT (1) LT3484922T (fr)
MA (1) MA45672A (fr)
MX (1) MX2018015853A (fr)
PT (1) PT3484922T (fr)
RS (1) RS68315B1 (fr)
SG (1) SG11201811431VA (fr)
SI (1) SI3484922T1 (fr)
UA (1) UA128304C2 (fr)
WO (1) WO2018011421A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900702T1 (it) 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
US20190338041A1 (en) * 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
CN111511762B (zh) * 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019057792A1 (fr) * 2017-09-19 2019-03-28 Mab Discovery Gmbh Anticorps cd40 agonistes
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
WO2020077635A1 (fr) 2018-10-19 2020-04-23 苏州丁孚靶点生物技术有限公司 Anticorps anti-cd137 et ses applications
SG11202104180WA (en) * 2018-10-30 2021-05-28 Peter Maccallum Cancer Inst Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
CN113454111A (zh) * 2018-11-06 2021-09-28 健玛保 抗体配制剂
CA3119865A1 (fr) * 2018-11-23 2020-05-28 Strike Pharma Ab Conjugues bi-specifiques
WO2020159368A1 (fr) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Nouveaux anticorps se liant au cd40
CN111269315B (zh) 2019-06-19 2022-04-08 北京智仁美博生物科技有限公司 针对bcma的单克隆抗体
US12703758B2 (en) 2019-06-19 2026-08-11 Changqing Genrix Biopharmaceutical Co., Ltd. Anti-CD3E/BCMA bispecific antibody and use thereof
WO2021156326A1 (fr) * 2020-02-04 2021-08-12 Genmab A/S Anticorps destinés à être utilisés en thérapie
WO2021155916A1 (fr) * 2020-02-04 2021-08-12 BioNTech SE Traitement impliquant une vaccination d'antigène et des agents de liaison se liant à pd-l1 et cd137
EP4137155A4 (fr) * 2020-04-17 2024-10-30 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. Préparation spécifiquement liée à cd137 et son utilisation
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
CN112321700A (zh) * 2020-09-21 2021-02-05 四川省人民医院 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
AU2022233547A1 (en) * 2021-03-09 2023-09-28 BioNTech SE Multispecific binding agents against cd40 and cd137 in therapy
WO2023285552A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
WO2023174521A1 (fr) 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
TW202409090A (zh) * 2022-05-12 2024-03-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
EP4590710A1 (fr) * 2022-09-20 2025-07-30 Currus Biologics Pty Ltd Procédé de sauvetage de cellules immunitaires épuisées
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
EP4719352A1 (fr) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Formulations et compositions de nanoparticules lipidiques
WO2025056180A1 (fr) 2023-09-15 2025-03-20 BioNTech SE Procédés de traitement faisant appel à des agents se liant à epcam et cd137 en combinaison avec des antagonistes de liaison à l'axe pd-1
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
KR20250116195A (ko) 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (fr) 1997-05-02 2005-07-20 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
MXPA02007473A (es) * 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
WO2002028481A2 (fr) 2000-10-02 2002-04-11 Chiron Corporation Methodes therapeutiques pour lutter contre les cellules b malignes
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2531118C (fr) 2003-07-01 2013-01-08 Immunomedics, Inc. Porteuses polyvalentes d'anticorps bispecifiques
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1945260B1 (fr) 2005-11-01 2012-10-24 Novartis AG Utilisations d'anticorps anti-cd40
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2158221B1 (fr) 2007-06-21 2018-08-29 MacroGenics, Inc. Di-anticorps covalents et leurs utilisations
EP2535350B1 (fr) 2007-09-26 2018-01-24 UCB Biopharma SPRL Fusions d'anticorps à double spécificité
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2010015792A1 (fr) 2008-08-06 2010-02-11 Argenta Discovery Limited Composés hétérocycliques contenant de l'azote utiles comme modulateurs bifonctionnels des récepteurs m3 et des récepteurs bêta-2
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
CA2781682A1 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispecifiques, analogues d'anticorps, compositions et procedes
GB201003293D0 (en) * 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
WO2012023053A2 (fr) 2010-08-16 2012-02-23 Novimmune S.A. Procédé de production d'anticorps multispécifiques et multivalents
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
IN2014CN03887A (fr) 2011-10-27 2015-10-16 Genmab As
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
WO2014006217A1 (fr) * 2012-07-06 2014-01-09 Genmab B.V. Protéine dimérique ayant des mutations triples
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2888763A1 (fr) 2012-10-30 2014-05-08 Apexigen, Inc. Anticorps anti-cd40 et procedes d'utilisation
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
KR102813816B1 (ko) * 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN106459165B (zh) 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
EP3180087B1 (fr) 2014-08-12 2019-03-13 Alligator Bioscience AB Polythérapies utilisant des anticorps anti-cd40
SMT201900702T1 (it) * 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
US10875926B2 (en) 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
EP3515951B1 (fr) 2016-09-23 2024-02-28 Merus N.V. Molécules de liaison qui modulent une activité biologique exprimée par une cellule
WO2018098370A1 (fr) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
WO2018187215A1 (fr) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques à titre d'agoniste de 4-1bb
WO2018213747A1 (fr) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
EA201990293A1 (ru) 2019-07-31
US20220033510A1 (en) 2022-02-03
NZ749274A (en) 2024-12-20
FI3484922T3 (fi) 2026-07-02
US11091557B2 (en) 2021-08-17
RS68315B1 (en) 2026-07-31
LT3484922T (lt) 2026-06-25
US20230089969A1 (en) 2023-03-23
US11939388B2 (en) 2024-03-26
EP4755464A3 (fr) 2026-08-19
US11440966B2 (en) 2022-09-13
IL264142B2 (en) 2025-08-01
JP7138630B2 (ja) 2022-09-16
JP2019533466A (ja) 2019-11-21
DK3484922T3 (da) 2026-07-27
CN109641959B (zh) 2023-08-22
US20200062853A1 (en) 2020-02-27
JP7750808B2 (ja) 2025-10-07
UA128304C2 (uk) 2024-06-05
AU2017296095A1 (en) 2019-01-17
IL264142A (en) 2019-02-28
SG11201811431VA (en) 2019-01-30
US12077596B2 (en) 2024-09-03
AU2017296095C1 (en) 2024-11-14
AU2017296095B2 (en) 2024-05-02
BR112019000512A2 (pt) 2019-04-24
PT3484922T (pt) 2026-07-20
KR20190028508A (ko) 2019-03-18
CN109641959A (zh) 2019-04-16
WO2018011421A1 (fr) 2018-01-18
US20210317225A1 (en) 2021-10-14
KR102632202B1 (ko) 2024-02-02
MX2018015853A (es) 2019-08-21
IL264142B1 (en) 2025-04-01
ES3072652T3 (en) 2026-07-03
EP3484922B1 (fr) 2026-04-29
KR20250097987A (ko) 2025-06-30
CN117247458A (zh) 2023-12-19
EP4755464A2 (fr) 2026-06-10
AU2024205418A1 (en) 2024-08-22
US20220064317A1 (en) 2022-03-03
JP2022184871A (ja) 2022-12-13
CA3030636A1 (fr) 2018-01-18
EP3484922A1 (fr) 2019-05-22
JP2025186475A (ja) 2025-12-23
US11084882B2 (en) 2021-08-10
US20200247899A1 (en) 2020-08-06
KR20240017129A (ko) 2024-02-06
SI3484922T1 (sl) 2026-07-31

Similar Documents

Publication Publication Date Title
IL264142A (en) Multispecific antibodies against cd40 and cd137
IL287019A (en) Compositions and methods for internalizing enzymes
MA49823A (fr) Anticorps dirigés contre pd-l1
EP3333192A4 (fr) Anticorps dirigé contre le glypican-3 et application associée
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
EP3341477A4 (fr) Nucléases crispr-cas9 modifiées
SG11201707663SA (en) Lyophilization of rna
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3464592A4 (fr) Amplification omega
EP3280418A4 (fr) Inhibiteurs de btk azacarbazole
EP3037812C0 (fr) Électrode à enzyme
GB201421085D0 (en) New enzyme inhibitors
EP3268125A4 (fr) Détermination de cellules à l'aide d'amplification
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
DK3365107T3 (da) Cellekultur
DK3137616T3 (da) Forøgelse af cellulær lipid produktion ved forøgelse af aktiviteten af diacylglycerolacyltransferase og formindskelse af aktiviteten af triacylglycerollipase
EP3349794A4 (fr) Anticorps anti-cd115
EP3381941A4 (fr) Anticorps anti-epha4
DK3630968T3 (da) Enzymer til glycananalyse
MA44067A (fr) Anticorps dirigés contre la quétiapine et utilisation associée
EP3448986A4 (fr) Culture de cellules
EP3183364A4 (fr) Procédés d'amplification d'arn
DK3371293T3 (da) Fermentering